|
|
|
The IMF is pleased to present the most comprehensive coverage of the XIth International Myeloma Workshop.
|
|
|
|
|
|
Angelo Vacca, MD
Department of Internal Medicine and Clinical Oncology
University of Bari Medical School
Bari, Italy
|
|
|
|
|
Douglas Joshua, MD
University of Sydney
Royal Prince Alfred and Concord Hospital
Camperdown, Australia
|
|
|
|
|
|
Ruben Carrasco, MD
Dana Farber Cancer Institute
Medical Oncology Dept.
Boston, MA, USA
(Presentation given by Giovanni Tonon) |
|
|
|
|
Giovanni Tonon, MD
Dana Farber Cancer Institute
Medical Oncology Dept.
Boston, MA, USA
|
|
|
|
|
Michio Kawano, MD
Laboratory of Cellular Signal Analysis
Graduate School of Medicine
Yamaguchi University
Ube, Japan
|
|
|
|
|
Peter Croucher, MD
Section of Musculoskeletal Science
University of Sheffield Medical School
Sheffield, UK
|
|
|
|
|
James Berenson, MD
Institute for Myeloma and Bone Cancer Research
Los Angeles, CA, USA
|
|
|
|
|
Evangelos Terpos, MD
Department of Hematology & Medical Research
251 General Airforce Hospital
Athens, Greece
|
|
|
|
|
G. David Roodman
University of Pittsburgh
Medicine/Hematology-Oncology
Pittsburgh, PA, USA
|
|
|
|
|
Marta Chesi, MD
Comprehensive Cancer Center
Mayo Clinic Arizona
Scottsdale, AZ, USA
|
|
|
print
KOS 2007: Mosaicism of Vessels in Patients with Myeloma and Therapeutic Approaches 
KOS 2007: The Role of T-Cells in Multiple Myeloma 
KOS 2007: Genetic Model of Multiple Myeloma 
KOS 2007: From Oncogenome Mining to Functional Validation of Multiple Myeloma Cancer Genes 
KOS 2007: Induction of Multi-Lineage Markers and Their Down-Regulation by IL-6 in Human Myeloma Cells 
KOS 2007: Pathophysiology of Myeloma Bone Disease 
KOS 2007: The Role of Bisphosphonates in the Management of Myeloma 
KOS 2007: The Role of Biochemical Markers of Bone Metabolism in Multiple Myeloma. Adverse Events of Bisphosphonates Administration 
KOS 2007: A transgenic mouse model that faithfully reproduces the pathogenesis, biology and clinical features of multiple myeloma 
back to top